NASDAQ:AVIR Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis $3.92 +0.02 (+0.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.78▼$3.9750-Day Range$3.17▼$3.9652-Week Range$2.77▼$4.60Volume188,095 shsAverage Volume351,757 shsMarket Capitalization$330.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Atea Pharmaceuticals alerts: Email Address Atea Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish3.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 2 Articles This WeekInsider TradingSelling Shares$65,253 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.79) to ($2.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector876th out of 936 stocksPharmaceutical Preparations Industry412th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Atea Pharmaceuticals.Read more about Atea Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.21% of the float of Atea Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAtea Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Atea Pharmaceuticals has recently increased by 5.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtea Pharmaceuticals does not currently pay a dividend.Dividend GrowthAtea Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVIR. Previous Next 2.3 News and Social Media Coverage News SentimentAtea Pharmaceuticals has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atea Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AVIR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atea Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,253.00 in company stock.Percentage Held by Insiders17.80% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.67% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Atea Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atea Pharmaceuticals are expected to decrease in the coming year, from ($2.79) to ($2.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atea Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atea Pharmaceuticals is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtea Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atea Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Atea Pharmaceuticals Stock (NASDAQ:AVIR)Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Read More AVIR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVIR Stock News HeadlinesJuly 18, 2024 | americanbankingnews.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 5.2% in JuneJuly 16, 2024 | americanbankingnews.comAtea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 3.2%July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | globenewswire.comAtea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceMay 22, 2024 | globenewswire.comAtea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024May 16, 2024 | markets.businessinsider.comAtea Pharmaceuticals: Assessing Bemnifosbuvir’s Prospects Amidst Clinical and Financial ChallengesMay 16, 2024 | investing.comAtea Pharmaceuticals Inc (AVIR)May 15, 2024 | msn.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | finance.yahoo.comAtea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...May 14, 2024 | investorplace.comAVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024May 14, 2024 | msn.comAtea Pharmaceuticals GAAP EPS of -$0.75 misses by $0.14May 14, 2024 | finance.yahoo.comAtea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comAtea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024April 29, 2024 | finanznachrichten.deAtea Pharmaceuticals, Inc.: Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024April 29, 2024 | globenewswire.comAtea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024March 27, 2024 | globenewswire.comAtea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsMarch 21, 2024 | edition.cnn.comAtea Pharmaceuticals, Inc.See More Headlines Receive AVIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVIR CUSIPN/A CIK1593899 Webwww.ateapharma.com Phone857-284-8891FaxN/AEmployees70Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-135,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.18% Return on Assets-27.48% Debt Debt-to-Equity RatioN/A Current Ratio13.28 Quick Ratio13.28 Sales & Book Value Annual Sales$351.37 million Price / Sales0.93 Cash FlowN/A Price / Cash FlowN/A Book Value$6.65 per share Price / Book0.58Miscellaneous Outstanding Shares84,220,000Free Float69,231,000Market Cap$326.77 million OptionableOptionable Beta0.18 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Jean-Pierre Sommadossi Ph.D. (Age 68)Founder, Chairman, CEO & President Comp: $1.04MMs. Andrea J. Corcoran J.D. (Age 62)CFO, Executive VP of Legal & Secretary Comp: $712.48kMr. Wayne Foster CPA (Age 55)Executive VP of Finance & Chief Accounting Officer Comp: $580.46kDr. Janet M. J. Hammond M.D. (Age 64)Ph.D., Chief Development Officer Comp: $789.47kDr. Maria Arantxa Horga M.D. (Age 56)Chief Medical Officer Comp: $679.58kMs. Jonae R. BarnesSenior Vice President of Investor Relations & Corporate CommunicationsMr. Ariyapadi N. KrishnarajVice President of MarketingMr. Adel Moussa Ph.D.Executive Vice President of ChemistryMr. Xiao-Jian Zhou Ph.D.Executive Vice President of Early Stage DevelopmentMr. John F. Vavricka (Age 61)Chief Commercial Officer Comp: $581.11kMore ExecutivesKey CompetitorsInovio PharmaceuticalsNASDAQ:INOSpyre TherapeuticsNASDAQ:SYRERelay TherapeuticsNASDAQ:RLAYOcular TherapeutixNASDAQ:OCULCullinan TherapeuticsNASDAQ:CGEMView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 26,627 shares on 7/26/2024Ownership: 0.316%SG Americas Securities LLCSold 14,089 shares on 7/12/2024Ownership: 0.017%Bruce PolskySold 17,544 sharesTotal: $61,228.56 ($3.49/share)Jean-Pierre SommadossiSold 1,006 sharesTotal: $4,024.00 ($4.00/share)Tidal Investments LLCBought 21,472 shares on 5/17/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions AVIR Stock Analysis - Frequently Asked Questions How have AVIR shares performed this year? Atea Pharmaceuticals' stock was trading at $3.05 at the start of the year. Since then, AVIR shares have increased by 28.5% and is now trading at $3.92. View the best growth stocks for 2024 here. How were Atea Pharmaceuticals' earnings last quarter? Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.14. When did Atea Pharmaceuticals IPO? Atea Pharmaceuticals (AVIR) raised $253 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO. Who are Atea Pharmaceuticals' major shareholders? Atea Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.32%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Jean-Pierre Sommadossi, Andrea Corcoran, Bruce Polsky, Wayne Foster and Polly A Murphy. View institutional ownership trends. How do I buy shares of Atea Pharmaceuticals? Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVIR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
